BAYRY
Ohio gets a new pharma neighbor
Bayer is opening its wallet: the German drugmaker says it’ll invest $2.2 billion in a new U.S. pharmaceutical manufacturing site in Ohio, with plans to create around 600 jobs. That’s not pocket change, even for a company with a global footprint.
Why this matters
This isn’t just about more bricks, beakers, and forklifts. Big pharma has been racing to put more production stateside, partly to shore up supply chains and partly because Washington loves a good “Made in America” storyline.
For Bayer, the move could mean:
- more control over supply and manufacturing
- a bigger U.S. presence in a market that matters a lot
- a chance to look less like a distant European exporter and more like a local operator
Big picture
The new Ohio site is another reminder that pharma manufacturing is becoming a geopolitically flavored business. If you’re an investor, the question isn’t just whether the plant gets built — it’s whether this kind of capex pays off in smoother operations, stronger margins, or just a fancier address with a lot of ribbon-cutting photos.